The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials.
Identifieur interne : 000124 ( Main/Corpus ); précédent : 000123; suivant : 000125The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials.
Auteurs : Eugenie R. Lumbers ; Sarah J. Delforce ; Kirsty G. Pringle ; Gary R. SmithSource :
- Frontiers in medicine [ 2296-858X ] ; 2020.
Abstract
Angiotensin-converting enzyme 2 (ACE2) is the receptor for COVID-19 (SARs-CoV-2). ACE2 protects the lung and heart from acute respiratory distress syndrome (ARDS) and acute myocarditis and arrhythmias, because it breaks down Angiotensin II, which has inflammatory effects in the lung and heart as well as in the kidney. When SARS-CoV-2 binds to ACE2, it suppresses it, so this protective action of ACE2 is lost. Death from COVID-19 is due to ARDS and also heart failure and acute cardiac injury. Drugs that prevent the inflammatory actions of Angiotensin II (i.e., Angiotensin receptor blockers, ARBs) prevent acute lung injury caused by SARS-CoV. Clinical trials are underway to test the risks and benefits of ARBs and angiotensin-converting enzyme inhibitors (ACEIs) in COVID-19 patients requiring hospitalization. Other potential treatments are also discussed.
DOI: 10.3389/fmed.2020.00248
PubMed: 32574336
PubMed Central: PMC7256451
Links to Exploration step
pubmed:32574336Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials.</title>
<author><name sortKey="Lumbers, Eugenie R" sort="Lumbers, Eugenie R" uniqKey="Lumbers E" first="Eugenie R" last="Lumbers">Eugenie R. Lumbers</name>
<affiliation><nlm:affiliation>School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Priority Research Centre for Reproductive Science, University of Newcastle, Callaghan, NSW, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Pregnancy and Reproduction Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Delforce, Sarah J" sort="Delforce, Sarah J" uniqKey="Delforce S" first="Sarah J" last="Delforce">Sarah J. Delforce</name>
<affiliation><nlm:affiliation>School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Priority Research Centre for Reproductive Science, University of Newcastle, Callaghan, NSW, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Pregnancy and Reproduction Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pringle, Kirsty G" sort="Pringle, Kirsty G" uniqKey="Pringle K" first="Kirsty G" last="Pringle">Kirsty G. Pringle</name>
<affiliation><nlm:affiliation>School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Priority Research Centre for Reproductive Science, University of Newcastle, Callaghan, NSW, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Pregnancy and Reproduction Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Smith, Gary R" sort="Smith, Gary R" uniqKey="Smith G" first="Gary R" last="Smith">Gary R. Smith</name>
<affiliation><nlm:affiliation>VP System Practice, International Society for the System Sciences, Pontypool, United Kingdom.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32574336</idno>
<idno type="pmid">32574336</idno>
<idno type="doi">10.3389/fmed.2020.00248</idno>
<idno type="pmc">PMC7256451</idno>
<idno type="wicri:Area/Main/Corpus">000124</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000124</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials.</title>
<author><name sortKey="Lumbers, Eugenie R" sort="Lumbers, Eugenie R" uniqKey="Lumbers E" first="Eugenie R" last="Lumbers">Eugenie R. Lumbers</name>
<affiliation><nlm:affiliation>School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Priority Research Centre for Reproductive Science, University of Newcastle, Callaghan, NSW, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Pregnancy and Reproduction Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Delforce, Sarah J" sort="Delforce, Sarah J" uniqKey="Delforce S" first="Sarah J" last="Delforce">Sarah J. Delforce</name>
<affiliation><nlm:affiliation>School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Priority Research Centre for Reproductive Science, University of Newcastle, Callaghan, NSW, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Pregnancy and Reproduction Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pringle, Kirsty G" sort="Pringle, Kirsty G" uniqKey="Pringle K" first="Kirsty G" last="Pringle">Kirsty G. Pringle</name>
<affiliation><nlm:affiliation>School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Priority Research Centre for Reproductive Science, University of Newcastle, Callaghan, NSW, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Pregnancy and Reproduction Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Smith, Gary R" sort="Smith, Gary R" uniqKey="Smith G" first="Gary R" last="Smith">Gary R. Smith</name>
<affiliation><nlm:affiliation>VP System Practice, International Society for the System Sciences, Pontypool, United Kingdom.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Frontiers in medicine</title>
<idno type="ISSN">2296-858X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Angiotensin-converting enzyme 2 (ACE2) is the receptor for COVID-19 (SARs-CoV-2). ACE2 protects the lung and heart from acute respiratory distress syndrome (ARDS) and acute myocarditis and arrhythmias, because it breaks down Angiotensin II, which has inflammatory effects in the lung and heart as well as in the kidney. When SARS-CoV-2 binds to ACE2, it suppresses it, so this protective action of ACE2 is lost. Death from COVID-19 is due to ARDS and also heart failure and acute cardiac injury. Drugs that prevent the inflammatory actions of Angiotensin II (i.e., Angiotensin receptor blockers, ARBs) prevent acute lung injury caused by SARS-CoV. Clinical trials are underway to test the risks and benefits of ARBs and angiotensin-converting enzyme inhibitors (ACEIs) in COVID-19 patients requiring hospitalization. Other potential treatments are also discussed.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32574336</PMID>
<DateRevised><Year>2020</Year>
<Month>06</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>7</Volume>
<PubDate><Year>2020</Year>
</PubDate>
</JournalIssue>
<Title>Frontiers in medicine</Title>
<ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation>
</Journal>
<ArticleTitle>The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials.</ArticleTitle>
<Pagination><MedlinePgn>248</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2020.00248</ELocationID>
<Abstract><AbstractText>Angiotensin-converting enzyme 2 (ACE2) is the receptor for COVID-19 (SARs-CoV-2). ACE2 protects the lung and heart from acute respiratory distress syndrome (ARDS) and acute myocarditis and arrhythmias, because it breaks down Angiotensin II, which has inflammatory effects in the lung and heart as well as in the kidney. When SARS-CoV-2 binds to ACE2, it suppresses it, so this protective action of ACE2 is lost. Death from COVID-19 is due to ARDS and also heart failure and acute cardiac injury. Drugs that prevent the inflammatory actions of Angiotensin II (i.e., Angiotensin receptor blockers, ARBs) prevent acute lung injury caused by SARS-CoV. Clinical trials are underway to test the risks and benefits of ARBs and angiotensin-converting enzyme inhibitors (ACEIs) in COVID-19 patients requiring hospitalization. Other potential treatments are also discussed.</AbstractText>
<CopyrightInformation>Copyright © 2020 Lumbers, Delforce, Pringle and Smith.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lumbers</LastName>
<ForeName>Eugenie R</ForeName>
<Initials>ER</Initials>
<AffiliationInfo><Affiliation>School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Priority Research Centre for Reproductive Science, University of Newcastle, Callaghan, NSW, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Pregnancy and Reproduction Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Delforce</LastName>
<ForeName>Sarah J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo><Affiliation>School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Priority Research Centre for Reproductive Science, University of Newcastle, Callaghan, NSW, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Pregnancy and Reproduction Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pringle</LastName>
<ForeName>Kirsty G</ForeName>
<Initials>KG</Initials>
<AffiliationInfo><Affiliation>School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Priority Research Centre for Reproductive Science, University of Newcastle, Callaghan, NSW, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Pregnancy and Reproduction Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Smith</LastName>
<ForeName>Gary R</ForeName>
<Initials>GR</Initials>
<AffiliationInfo><Affiliation>VP System Practice, International Society for the System Sciences, Pontypool, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Front Med (Lausanne)</MedlineTA>
<NlmUniqueID>101648047</NlmUniqueID>
<ISSNLinking>2296-858X</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE2</Keyword>
<Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">SARS- CoV-2</Keyword>
<Keyword MajorTopicYN="N">cardiovascular disease</Keyword>
<Keyword MajorTopicYN="N">lung injury</Keyword>
<Keyword MajorTopicYN="N">renin-angiotensin system (RAS)</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>6</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>6</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32574336</ArticleId>
<ArticleId IdType="doi">10.3389/fmed.2020.00248</ArticleId>
<ArticleId IdType="pmc">PMC7256451</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Science. 2020 Mar 13;367(6483):1260-1263</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32075877</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Shock. 2016 Sep;46(3):239-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27082314</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Travel Med. 2020 May 18;27(3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32186711</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Allergy. 2020 Feb 19;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32077115</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2004 Jun;203(2):631-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15141377</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Invest. 2009 Jul;39(7):618-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19453650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Jul 7;436(7047):112-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16001071</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Mar 26;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32215613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Mar 27;367(6485):1444-1448</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32132184</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hypertens. 2012 Feb;30(2):375-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22179088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Res. 2020 Jun 5;126(12):1671-1681</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32302265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19970-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19901337</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Pharm Ther. 2018 Apr;43(2):189-195</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28895159</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Life Sci. 2006 Apr 4;78(19):2166-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16303146</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1967 Nov 25;216(5117):762-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4294626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2013 Jul;42(1):198-210</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23100504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res. 2017 Nov;125(Pt A):21-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28619367</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Pharm Des. 2003;9(9):715-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12570789</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Apr 16;181(2):281-292.e6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32155444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2373-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18849338</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Biochem Cell Biol. 2012 Mar;44(3):465-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22155301</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Renal Physiol. 2014 Apr 15;306(8):F812-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24553436</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 May 28;181(5):1016-1035.e19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32413319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2009 Mar;156(1-2):19-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19027037</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Virol J. 2010 May 25;4:76-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20700397</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Cell Physiol. 2008 Nov;295(5):C1169-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18768926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2002 Jun 20;417(6891):822-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12075344</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med. 2020 Apr;46(4):586-590</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32125455</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Dec;79(23):14614-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16282461</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Future Virol. 2010 Mar;5(2):145-161</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32201502</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Res. 2007 Jul 1;75(1):29-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17499227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15010527</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2008 Nov;89(Pt 11):2741-2745</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18931070</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Mar 26;368:m1091</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217556</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Mar 27;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219357</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2016 Sep;68(3):549-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27480841</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2003 Oct 7;108(14):1679-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14504185</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med Exp. 2015 Dec;3(1):44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26215809</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2005 May 24;111(20):2605-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15897343</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2005 Aug;11(8):875-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16007097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Perinatol. 2008 Dec;28 Suppl 3:S108-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19057599</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2007 May;212(1):1-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17464936</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2006 Apr;47(4):718-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16505206</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Dev Res. 2020 Mar 4;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32129518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1992 Jun 4;357(6377):420-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1350662</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacokinet. 2013 Sep;52(9):783-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23681967</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000124 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000124 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CardioCovidV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32574336 |texte= The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32574336" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CardioCovidV1
![]() | This area was generated with Dilib version V0.6.35. | ![]() |